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OBJECTIVE—To estimate the impact of diabetes on mortality in patients after ﬁrst major
lower extremity amputation (LEA).
RESEARCH DESIGN AND METHODS—Using claims data of a nationwide statutory
healthinsurance,weassessedalldeathsinacohortofall444patientswithaﬁrstmajorLEAsince
2005 (71.8% male; mean age 69.1 years; 58.3% diabetic; 43% with amputation above the knee)
up to 2009. Using Cox regression, we estimated the time-dependent hazard ratios to compare
patients with and without diabetes.
RESULTS—The cumulative 5-year mortality was 68% in diabetic and 59% in nondiabetic
individuals. In the ﬁrst course, mortality was lower in diabetic compared with nondiabetic
patients. Later, the diabetes risk increased yielding crossed survival curves after 2 to 3 years
(time dependency of diabetes; P = 0.003). Age- and sex-adjusted hazard ratios for diabetes were
as follows: 0–30 days: 0.50 [95% CI 0.31–0.84]; 31–60 days: 0.60 [0.25–1.41]; 61 days to
6 months: 0.75 [0.38–1.48]; .6–12 months: 1.27 [0.63–2.53]; .12–24 months: 1.65 [0.88–
3.08]; .24–36 months: 2.02 [0.80–5.09]; and .36–60 months: 1.91 [0.70–5.21]. The pattern
was similar in both sexes. In the full model, signiﬁcant risk factors for mortality were age (1.05;
1.03–1.06), amputation above the knee (1.50; 1.16–1.94), and quartile category 3 or 4 of the
number of prescribed medications (1.64; 1.12–2.40 and 1.76; 1.20–2.59). Further adjustment
for comorbidity did not alter the results.
CONCLUSIONS—Inthispopulation-basedstudy,wefoundatime-dependentmortalityrisk
of diabetes following ﬁrst major LEA, which may be in part a result of a healthier lifestyle in
diabetic patients or the access to speciﬁc treatment structures in diabetic individuals.
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L
ower extremity complications, par-
ticularly ulceration and amputation,
are signiﬁcant sources of morbidity
in the diabetic population. Although the
reduction of lower extremity amputation
(LEA) in diabetes has frequently been
cited as a primary objective by health
systems and organizations (1,2), diabetic
individuals still have a largely increased
LEA risk compared with nondiabetic pa-
tients (3,4). Avoidance of amputation
should not only be targeted because of
the associated economic consequences
(high costs because of repeated hospital-
izations, rehabilitation, home care, and
social-service support) but also because
of quality-of-life issues. Alternative treat-
ment options might seem costly in the
short term, but most cost-effectiveness
analyses that also considered the long-
term perspective have concluded that
treatment alternatives in which the limb
is saved are most cost effective (see
Supplementary Ref. 1). Furthermore, di-
abetes has been considered to be associ-
ated with an excess mortality in patients
after LEA, in particular in the periopera-
tive period and during the ﬁrst year (5,6).
Some studies found contrasting results,
with similar or reduced mortality in dia-
betic compared with nondiabetic patients
(7–11; and Supplementary Refs. 2–4).
However, several studies are not popu-
lation based but use data from spe-
cialized diabetes centers or had short
follow-up periods. Thus results remain
controversial.
Hence, the aim of our study was to
evaluate the mortality risk in diabetic and
nondiabetic individuals after a ﬁrst major
LEA since 2005 up to 2009 in Germany,
using claimdata of anationwidestatutory
health insurance.
RESEARCH DESIGN AND
METHODS
Study population and data
assessment
We used data of a cohort of patients with
incident LEA, for which analyses on in-
cidence have been published elsewhere
(3). In brief, these patients were derived
from the Gmünder ErsatzKasse (GEK), a
statutory health insurance company that
insured 1.6 million people located in all
regions of Germany (1.9% of the German
population). We included all people who
were members of the GEK for at least 1
year within the period 1 January 2004 to
31 December 2007. Diabetic patients
were deﬁned according to an established
procedure (12) as subjects with at least
one of the following characteristics: 1)d i -
abetesdiagnosis(ICDE10-E14)inatleast
three of four consecutive quarters, 2)a t
least two prescriptions of antidiabetic
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ORIGINAL ARTICLEmedication (ATC code A10) within 12
months, or 3) at least one prescription of
an antidiabetic medication and one diabe-
tes diagnosisorone measurement ofblood
glucose or HbA1c within 12 months. We
assessed all incident LEAs between 2005
and 2007 in patients with an amputation-
free period of at least 1 year. Lower limb
amputations were classiﬁed according to
a previous study (3) using speciﬁc opera-
tion procedure codes (OPS codes 5–
864.3,5 –865.3,a n d5 –869.0) of the
hospital discharge documentation. A total
of 994 patients with a ﬁrst minor or major
LEA were included.
The current study was restricted to
major amputations (any resection proxi-
mal to the midtarsal level, according to
the 2007 International Consensus of the
Diabetic Foot [13]). Patients with minor
amputations were further followed up
until 31 December 2009 and were in-
cluded if a major amputation occurred.
A total of 454 patients with an incident
major LEA were studied, of whom 418
had their event between 2005 and 2007.
The index date was the day of the ﬁrst
major amputation. We further excluded
all people coinsured as a dependent and
members who left the GEK for reasons
other than death within the study period
(n =1 0 ) .B o t hc r i t e r i aw e r ea p p l i e dt o
avoid informative censoring in the sur-
vival analysis (e.g., an insurance period
ends because of death but this reason
might not be documented in these cases).
Our ﬁnal cohort, therefore, comprised
444 patients with a ﬁr s tm a j o rL E Ab e -
tween 2005 and follow up to 2009.
We further used medication claims
datafortheyearprecedingtheindexdate.
Treatment with cardiovascular drugs
(b-blockers, ACE inhibitors, sartans, sta-
tins, ezetimibe, ﬁbrates, and clopidogrel)
and antidiabetic drugs (insulin, oral anti-
diabetic agents) was assessed. Because it
has been shown that the number of dis-
tinct medications prescribed in the previ-
ous year is a good predictor of mortality
(14), we included this indicator as a
comorbidity measure. Furthermore, we
assessed the following outpatient diagno-
ses:1)hypertension(ICD-10:I10-I15),2)
chronic ischemic heart diseases (ICD-10:
I20-I21, I25), 3) cerebral ischemia/
chronic stroke (ICD-10: G45, I60-I64,
I69), and 4) renal failure (ICD-10: N18-
N19) coded according to a previous
study using German claims data (see
Supplementary Ref. 5). At least one of
these diagnoses had to be recorded in a
1-year period (including the quarter of
the index date and the preceding three
quarters). Quarters had to be chosen be-
c a u s et h i si st h eb a s i ct i m ep e r i o df o r
coding diagnoses in outpatient care in
Germany.
Statistical analysis
Target variable was the time from the ﬁrst
major LEA up to death or the end of the
study period (31 December 2009),
whichever came ﬁrst. We assessed sur-
vival with the Kaplan Meier estimator,
stratiﬁed for diabetes. Crude differences
between diabetic and nondiabetic indi-
viduals were planned to be statistically
compared using the log-rank test, if the
proportional hazard assumption was not
violated. But because survival curves of
the diabetic and the nondiabetic group
were crossing, proportional hazards
could not be assumed, which was statis-
tically tested using the test proposed by
Grambsch and Therneau (15). We then
performed Cox regression using discrete
time intervals to model the time depen-
dency of diabetes (16) and to evaluate
predictors of death in multivariate analy-
ses. As predictors, we included diabetes,
interaction of diabetes with the discrete
time intervals (30 and 60 days, 6, 12,
24, 36, and 60 months), and age (as con-
tinuous variable). In a second model, the
location of the amputation (below or
above knee) and the number of pre-
scribed medications, which were catego-
rized into quartiles, were added as further
independent variables. In a sensitivity
analysis,wealsoincludedtheabovegiven
outpatient diagnoses for hypertension,
chronic ischemic heart diseases, cerebral
ischemia/chronic stroke, and renal failure.
The Cox regression was also per-
formed stratiﬁed for men and women.
All analyses were performed using R
(A Language and Environment for Statis-
tical Computing, Release 2.10.1; R Foun-
dation for Statistical Computing, http://
www.R-project.org), and the results of
the Cox models were veriﬁed using the
Statistical Analysis Systems SAS (SAS for
Windows XP Professional, Release 9.2
TS2M0; SAS Institute, Cary, NC).
RESULTS—Results did not differ sub-
stantially between men and women. Thus
we report the results for the whole pop-
ulation.
Baseline characteristics of the study
population
Of the 444 individuals with incident
major amputation between 2005 and up
to 2009, 319 (71.8%) were male, and
mean age (SD) was 69.1 (11.7) years. Of
the individuals, 259 (58.3%) of them had
diabetes and 192 (43.2%) of the LEAs
were above the knee. Diabetic patients
were slightly older, more likely to be
male, and had more prescribed medica-
tionscomparedwithnondiabeticindivid-
uals. The proportion of amputations
above the knee was lower in diabetic
than in nondiabetic patients. Diabetic
patients were more likely to have a di-
agnosisofhypertension,chronicischemic
heart diseases, cerebral ischemia/chronic
stroke, or renal failure. Table 1 shows the
description of the subjects with incident
major amputation, stratiﬁed for diabetes.
Survival and mortality in the study
population
Overall, 245 individuals died within the
study period of up to 5 years, 146 and 99
with and without diabetes, respectively.
The mean observation time per patient
(SD) was 1.9 (1.6) years.
Figure 1 shows the Kaplan-Meier
curves crossing each other after about 2
years in the whole population (number of
survivors under the curves in Table 2).
The assumption of proportional hazards
seemed to be violated: there was a signif-
icant time dependency of diabetes (P =
0.003). This means corresponding to the
ﬁgure that the relative mortality risk as a
result of diabetes was time dependent:
in the ﬁrst time after LEA, diabetic indi-
viduals had better survival. But in the
time course the diabetes risk increased
yielding crossed survival curves after
about 2 to 3 years. The relative mortality
risk for diabetes, adjusted for sex and
age, was as follows: baseline 0–30 days:
0.50 [95% CI 0.31–0.84]; 31–60 days:
0.60 [0.25–1.41]; 61 days to 6 months:
0.75 [0.38–1.48]; .6t o1 2m on th s :1 . 2 7
[0.63–2.53]; .12 to 24 months: 1.65
[0.88–3.08]; .24 to 36 months: 2.02
[0.80–5.09]; and .36 to 60 months:
1.91 [0.70–5.21]. As expected, age was
signiﬁcantly associated with mortality.
Cumulative mortality after 1 month,
1 year, and 5 years, as derived from the
Kaplan-Meier estimates, was 10, 31, and
68% in diabetic and 19, 40, and 59% in
nondiabetic individuals, respectively.
Model 2 in Table 3 shows the results
whentheLEAlocationandthenumberof
prescribed medications are included as
further predictors. The hazard ratios of
model 1 remained. Amputation above
the knee (1.50; 1.16–1.94), and quartile
category 3 or 4 of number of prescribed
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Icks and Associatesmedications (1.64; 1.12–2.40 and 1.76;
1.20–2.59) were both signiﬁcantly asso-
ciated with mortality.
The inclusion of hypertension,
chronic ischemic heart diseases, cerebral
ischemia/chronic stroke, and renal failure
in a sensitivity analysis did not alter our
ﬁndings (data not shown). Furthermore,
none of these variables were statistically
signiﬁcant or associated with mortality.
CONCLUSIONS
Study ﬁndings and implications
In this population-based study we could
analyze survival in patients with incident
major amputation in Germany up to 5
years (2005–2009), with a focus on dia-
betes as a predictor. As expected, we
found a high mortalityin this population.
After3yearsfollow-up,morethan50%of
the patients in our cohort had died. In-
terestingly, the inﬂuence of diabetes in
our study was signiﬁcantly time depen-
dent: in the ﬁrst time after incident LEA,
mortality was lower in diabetic than in
nondiabetic individuals. There was an in-
creasing trend of diabetes risk during ob-
servation time, and after about 2 to 3
years, diabetic individuals had a higher
mortality than nondiabetic individuals.
The number of prescribed medications,
included as a proxy for comorbidity,
and the amputation level were signiﬁ-
cantly associated with mortality; how-
ever, they did not alter these estimates.
Lookingforanexplanationofourﬁnding,
one could argue that diabetic individuals
have more comorbidities, as indicated by
medications and outpatient diagnoses,
butare,however,morecloselymonitored
by several specialists because of their
chronic disease, and if problems arise
they are identiﬁed and treated early. In
Germany, nationwide disease manage-
mentprogramsfordiabeteshavebeenim-
plemented since 2003. These programs
deﬁned contents and time frames for the
treatment of diabetes and its complica-
tions,andtheyprovidedinterfacesamong
the different levels of care. Diabetic indi-
viduals were more likely to have an am-
putation below the knee eventually
because of the more distally pronounced
distribution pattern of peripheral arterial
disease compared with nondiabetic pa-
tients (17,18). In previously published
series, patients with below-knee amputa-
tion had been reported to have signiﬁ-
cantly better survival outcomes than
above-knee amputees (7,19,20). When
we stratiﬁed our analyses for amputation
level, the time dependency of diabetes
seemed to be only present for below-
knee amputations, not for amputations
above the knee (data not shown). How-
ever, the case numbers were too low to
yield valid estimates. Further analyses
are warranted. In the above-mentioned
disease management programs, networks
of specialized physicians have been intro-
duced in various German regions and are
thought to be responsible for a recently
Table 1—Description of the study population: patients with ﬁrst LEA during
2005 to 2009 (GEK insurants, Germany)
Diabetes No diabetes All
n 259 185 444
Mean age (years) (SD)
1 69.3 (10.7) 68.8 (13.1) 69.1 (11.7)
Sex (% male) 75.7 66.5 71.8
Above-knee amputation (%) 37.5 51.4 43.2
Number of prescribed medications
2
First quartile 11 6 8
Median 16 11 14
Third quartile 21 16 19
Maximum 47 37 47
Insulin therapy (%) 62.5 — 36.5
Oral antidiabetic medication (%)
2 38.6 — 22.5
Cardiovascular medication (%)
2,3 87.3 63.8 77.5
Diagnoses in outpatient care
4
Hypertension (%) 79.2 62.7 72.3
Chronic ischemic heart diseases (%) 46.7 32.4 40.8
Cerebral ischemia/chronic stroke (%) 25.9 20.5 23.6
Renal failure 31.7 13.5 24.1
1Age at time of ﬁrst major LEA;
2substances, in the year before ﬁrst major LEA;
3b-blockers, ACE inhibitors,
sartans,statins,ezetimibe,ﬁbrates,andclopidogrel;
4inthequarteroftheﬁrstmajorLEAandinthepreceding
3 quarters (e.g., 1 year).
Figure 1—Crude survival curves after ﬁrst major LEA (GEK insurants, Germany, 2005–2009).
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Diabetes impact on mortality after amputationobserved decline in major amputation
rates as well as reductions of the excess
amputation risk because of diabetes in
German diabetic populations (3,21).
One might argue that even those diabetic
patients in whom major amputation
cannot be avoided might proﬁtf r o mi m -
proved treatment structures by achieving
more distal major amputation levels,
tighter glycemic control, and more ag-
gressive cardiovascular risk management.
Such a concept has been proven to be ef-
fective by improving 5-year survival rates
in diabetic foot ulcer patients recently
(22). In this context the observed larger
number of prescribed medications in di-
abetic patients also might be a hint for
more aggressive management of cardio-
vascular risk factors, not only a marker
of comorbidity.
Other factors may play a role, like a
lower proportion of smokers among di-
abetic individuals undergoing amputa-
tion compared with their nondiabetic
counterparts (see Supplementary Ref. 2).
H o w e v e r ,i no u rd a t aw eh a v en oi n f o r -
mation about detailed clinical or lifestyle
variables, e.g., smoking habits or glyce-
miccontrol,and onlylimited information
about history of coronary or cerebrovas-
cular events, chronic heart failure, and re-
nal function. Exact causes of death also
cannot be determined by our data.
Comparison with other studies
The 1-year mortality of diabetic patients
in our study (31%) was comparable with
the numbers from other studies (31–
34%) (7,11,23). The 5-year mortality in
diabetic patients in our cohort showed
conformity with those from the study of
Aulivola et al. (7) (68 and 69%, respec-
tively) but was lower than reported from
other cohorts investigated in the 1990s
reporting 80–90% mortality after 5 years
(5,10). Mortality reported from nondia-
betic patients in other studies showed
much more variability, probably because
of more heterogenous patient cohorts
(1-year: 29–43%, 5-years: 49–77%) (5,7,
8,10,11,23).
Several studies evaluated mortality
after incident amputations in diabetic
compared with nondiabetic patients.
Diabetes has been considered to be asso-
ciated with an excess mortality in patients
after LEA, in particular in the perioper-
ative period and during the ﬁrst year
(5,6). Some studies found contrasting re-
sults, with similar mortality in diabetic
compared with nondiabetic patients (7–
11,23; and Supplementary Refs. 2–4).
However, several studies were not popu-
lation based but used data from special-
ized diabetes centers. Only a few studies
lookedovera5-yearperiod.Animproved
survival of diabetic patients 1 and 2 years
after major amputation compared with
nondiabetic patients and a loss of this dif-
ference during longer follow-up periods
has been described also by Pohjolainen
and Alaranta (10). A few other studies
found similar early death rates (up to 3
years) for diabetic and nondiabetic pa-
tients following major amputation with
worsening of the prognosis for diabetic
patients during further observation (up
to 10 years) (7–9). Most other studies
did not evaluate an interaction between
diabetes and time (5,6,9,23). Thus study
results remain conﬂicting, and further
studies are warranted to conﬁrm and ex-
plain our ﬁndings.
Study limitations and strengths
Several limitations have to be considered.
First, in particular in the last years of ob-
servation, the case numbersare low,lead-
ingtoalackofpowertodetectstatistically
signiﬁcant differences between patients
with and without diabetes. Second, we
have only limited information about clin-
ical variables and do not know patients’
lifestyles. However, we included the
number of prescribed drugs as well as
outpatient diagnoses of relevant comor-
bidities. We also had no information
about the reason of amputation and thus
couldnotexcludetraumaticamputations.
However, the proportion of amputations
as a result of trauma can be considered to
be low (see Supplementary Ref. 6). Fi-
nally, the insurants of the GEK are not
representative for the German population
with respect to age, sex, and socioeco-
nomic position (24), which might have
an impact on morbidity and on the utili-
zation of health care resources. Thus a
translation of our results in other popula-
tions should be performed with caution.
However, the incidence of LEA in our
population was well in line with the in-
cidence of LEA in a study based on hos-
pital records in a German region as was
the proportion of patients with diabetes
(21).
Table 3—Predictors for mortality after ﬁrst major LEA, Cox regression (GEK insurants,
Germany, 2005–2009)
HR for death (95% CI)
Model 1 Model 2
Diabetes
30–30 days 0.50 (0.30–0.84)* 0.44 (0.26–0.74)*
330–60 days 0.60 (0.25–1.41) 0.52 (0.22–1.23)
360 days to 6 months 0.75 (0.38–1.48) 0.65 (0.32–1.29)
36t o1 2m o n t h s 1 . 2 7( 0 . 6 3 –2.53) 1.11 (0.55–2.32)
312 to 24 months 1.65 (0.88–3.08) 1.46 (0.78–2.76)
324 to 36 months 2.02 (0.80–5.09) 1.76 (0.69–4.46)
336 to 60 months 1.91 (0.70–5.21) 1.64 (0.60–4.49)
Age (years) (continuously, per year) 1.05 (1.04–1.07)* 1.05 (1.04–1.06)*
Sex (men vs. women) 1.01 (0.77–1.34) 0.98 (0.74–1.29)
Location of amputation (above vs. below knee) — 1.50 (1.12–2.40)*
Quartile category of number of prescribed
medications (baseline: quartile 1 [0–8])
2[ 8 –14] — 1.16 (0.79–1.70)*
3[ 1 4 –19] — 1.64 (1.12–2.40)*
4[ 1 9 –47] — 1.76 (1.20–2.59)
*P , 0.05.
Table 2—Survival after ﬁrst major LEA (GEK insurants, Germany, 2005–2009)
Survivors
Time
1 Month 1 Year 2 Years 3 Years 4 Years 5 Years
No diabetes 81 (75–86) 60 (53–67) 52 (45–60) 48 (41–56) 43 (35–52) 41 (33–50)
Diabetes 90 (86–93) 69 (64–75) 55 (50–62) 46 (40–53) 35 (29–43) 32 (24–41)
Data are % (95% CI).
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Icks and AssociatesThe main strength of our study is that
wewere ableto analyze alarge population-
based dataset without selection with re-
spect to diabetes complications and that
diabetes status could directly be assessed
at study entry.
In conclusion, in our German
population-based study, we found a high
mortality in patients with a ﬁrst major
amputation.Interestingly,theinﬂuenceof
diabetes was time dependent: in the ﬁrst
~2 to 3 years after ﬁrst LEA, mortality was
l o w e ri nd i a b e t i ct h a ni nn o n d i a b e t i c
individuals. Only thereafter, diabetic pa-
tients had a higher mortality than non-
diabetic patients. Our observation is in
contrast with several, but not all, studies.
Possible explanations may be differences
in comorbidities, the access to speciﬁc
treatment structures for diabetic patients,
or smoking habits, as indicated by a
higher proportion of above-knee ampu-
tationsinnondiabeticpatients.However,
resultsremainconﬂicting,andfurtherstud-
ies are warranted to conﬁrm and explain
the results.
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